Pharmacokinetics of PP353, a formulation of linezolid for intervertebral disc administration, in patients with chronic low back pain and Modic change Type 1: A first‐in‐human, Phase 1b, open‐label, single‐dose study

Pharmacokinetics of PP353, a formulation of linezolid for intervertebral disc administration, in patients with chronic low back pain and Modic change Type 1: A first‐in‐human, Phase 1b, open‐label, single‐dose study

Abstract Background Bacterial infection of the intervertebral disc is difficult to treat because the tissue is usually not vascularized and systemic antibiotic therapy may not reach optimal antibacterial exposure. Here we characterize the safety, tolerability, and pharmacokinetics of PP353, a suspen...

Full description

Saved in:
Bibliographic Details
Main Authors: Shiva S. Tripathi, Robert Sneath, Aprajay Golash, Parag Desai, Duncan McHale, Sarah Guest, Charlie Brindley, Paul Cummings, Shane Smith, Conrad Stroud, Graham Scott, Steve Ruston, Lloyd Czaplewski
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:JOR Spine
Subjects:
chronic low back pain
intervertebral disc
intradiscal
linezolid
Modic
pharmacokinetics
Online Access:https://doi.org/10.1002/jsp2.70009
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jsp2.70009

Similar Items